Business
Sisram Medical Announces 2024 Annual Results
Sisram Medical Ltd (the "Company" or "Sisram", 1696.HK; together with its subsidiaries collectively referred to as the "Group"), a global consumer wellness group, featuring a distinguished synergistic ecosystem of business building blocks and consumer-focused approaches including Energy-Based Devices (EBD), Injectables, alongside other complementary offerings, announced its audited consolidated annual results for the year ended December 31, 2024 (the "Reporting Period").
About this update from Sisram Medical Ltd.
[{"type":"text","content":"New product launches drive double-digit growth in key markets and deliver market outperformance amid economic challenges","length":120,"tagName":"p","attribs":{}},{"type":"text","content":"HONG KONG, March 19, 2025 /PRNewswire/ -- Sisram Medical Ltd (the "Company" or "Sisram", 1696.HK; together with its subsidiaries collectively referred to as the "Group"), a global consumer wellness group, featuring a distinguished synergistic ecosystem of business building blocks and consumer-focused approaches including Energy-Based Devices (EBD), Injectables, alongside other complementary offerings, announced its audited consolidated annual results for the year ended December 31, 2024 (the "Reporting Period").","length":578,"tagName":"p"},{"type":"text","content":"FINANCIAL HIGHLIGHTS","length":20,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Revenue was US$349.1 million, representing a decrease of 2.8% YoY.","length":66,"tagName":"p"}]},{"val":[{"type":"text","content":"Gross profit margin was 62.1%, representing an increase of 1.0 percentage point from 61.1% in 2023.","length":99,"tagName":"p"}]},{"val":[{"type":"text","content":"Revenue portion derived from direct sales for the year ended December 31, 2024, was 87% of total revenue, as compared to 78% for the corresponding period in 2023. Revenues in Asia Pacific, European, Middle East and Africa were US$116.2 million, US$50.5 million, US$34.6 million, increased by 6.0%, 0.7%, and 27.1%, respectively. Revenue in North America was US$137.4 million, representing a decrease of 12.4% YoY.","length":413,"tagName":"p"}]},{"val":[{"type":"text","content":"Net profit was US$28.8 million, representing a decrease of 12.6% YoY.","length":69,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":647,"olType":false},{"type":"text","content":"FINAL DIVIDEND","length":14,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"The Board has resolved to declare a final dividend of HK$0.126 (inclusive of tax) per share for the year ended December 31, 2024.","length":129,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":129,"olType":false},{"type":"text","content":"KEY ACHIEVEMENTS","length":16,"tagName":"p"},{"type":"text","content":"Confidence in Sisram's Core Platform Reaches an...